Search

Displaying results 6051 - 6060 of 10000 in total
  1. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    It can be subcutaneously administered to initiate an immune response in case of an allergic reaction. … Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen.

  2. Drug

    Garlic oil

    go.drugbank.com/drugs/DB15989
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Lorajmine

    go.drugbank.com/drugs/DB13651
    Experimental

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ia
  4. Drug

    Daidzein

    go.drugbank.com/drugs/DB13182
    Investigational

    Categories: Topoisomerase II Inhibitors
  5. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  6. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect … LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol

  7. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

  8. Drug

    Rezivertinib

    go.drugbank.com/drugs/DB21471
    Investigational

    Rezivertinib is under investigation in clinical trial NCT06955325 (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations). … Rezivertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Rezivertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  9. Drug

    Dibenzepin

    go.drugbank.com/drugs/DB13225
    Approved

    Dibenzepin is approved for use in Europe.

  10. Drug

    IR502

    go.drugbank.com/drugs/DB06463
    Experimental

    IR502 (Zorcell) is a potential treatment for psoriasis.